In the remaining two studies, a total of 658 breast cancer patients were included showing no changes in the levels of Gal-3 in patients receiving breast cancer therapies including anthracyclines and/or trastuzumab nor an association with the development of CTRCD in these patients [98,136]. Here, LGALS3 is linked to breast carcinoma.